Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 2400Neoplasms 1817Carcinoma, Non-Small-Cell Lung 1598Prostatic Neoplasms 1306Colorectal Neoplasms 1139Lung Neoplasms 985Neoplasm Metastasis 836Multiple Myeloma 794Leukemia, Myeloid, Acute 767Ovarian Neoplasms 677Pancreatic Neoplasms 662Melanoma 660Squamous Cell Carcinoma of Head and Neck 584Carcinoma, Hepatocellular 571Recurrence 564Brain Neoplasms 528Glioblastoma 515Head and Neck Neoplasms 503Stomach Neoplasms 498Triple Negative Breast Neoplasms 465Lymphoma 456Uterine Cervical Neoplasms 453Carcinoma, Renal Cell 424Precursor Cell Lymphoblastic Leukemia-Lymphoma 408Lymphoma, Non-Hodgkin 390Endometrial Neoplasms 384Sarcoma 371Lymphoma, Follicular 358Urinary Bladder Neoplasms 355Hematologic Neoplasms 355

Interventions

cabozantinib 1Prednisone 1Nivolumab 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Metastatic Hormone Refractory Prostate Cancer × 1 year × Clear all
NCT04477512 2025-11-12

Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)

Washington University School of Medicine

Phase 1 Completed
18 enrolled
Genitourinary

Metastatic Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡